The role of hepatocyte cAMP/PDE4 in alcohol-induced liver steatosis and injury

肝细胞cAMP/PDE4在酒精性肝脂肪变性和损伤中的作用

• 批准号: 8638593
• 负责人: Leila Gobejishvili
• 金额: $ 21.56万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-02-05 至 2016-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8638593
• 关键词: ADD-1 protein; Acute; Adenylate Cyclase; Affect; Alcoholic Liver Diseases; Alcohols; Anabolism; Animal Feed; Apoptosis; Apoptotic; Cause of Death; Cell physiology; Cessation of life; Chronic; Cirrhosis; Clinical Treatment; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic AMP-Responsive DNA-Binding Protein; Data; Development; Endotoxins; Enzymes; Ethanol; FDA approved; Family; Fatty Acids; Fatty Liver; Fibrosis; Future; Genes; Glucocorticoids; Goals; Hepatic; Hepatocyte; Hepatorenal Syndrome; Hepatotoxicity; Homeostasis; Hydrolysis; In Vitro; Individual; Inflammatory; Injury; Injury to Liver; Intervention; Knock-out; Kupffer Cells; Label; Liver; Liver diseases; Metabolism; Mus; Patients; Pentoxifylline; Peroxisome Proliferator-Activated Receptors; Pharmacotherapy; Phosphodiesterase Inhibitors; Phosphorylation; Play; Predisposition; Prevention; Regulation; Role; Rolipram; Second Messenger Systems; Severities; Staging; Steroid Resistance; Steroid therapy; Stimulus; System; TNF gene; Therapeutic; Toxic effect; United States; Up-Regulation; Work; alcohol effect; alcohol exposure; alcohol response; base; chronic alcohol ingestion; cytokine; fatty acid oxidation; feeding; in vivo; inhibitor/antagonist; intervention effect; lipid biosynthesis; lipid metabolism; liver injury; macrophage; monocyte; mortality; oxidation; phosphoric diester hydrolase; problem drinker; public health relevance; receptor; response; second messenger; translational study

DESCRIPTION (provided by applicant): Alcoholic liver disease (ALD) remains a leading cause of death from liver disease in the United States. Steatosis is the initial, most frequent hepatic manifestation that occurs in response to acute as well as chronic ethanol consumption. Although steatosis is reversible, it is now established that the severity of steatosis predicts the progression of liver disease to more advanced stages including fibrosis and cirrhosis. Alcohol causes hepatic steatosis by enhancing de novo lipogenesis and impairing fatty acid beta-oxidation system with subsequent susceptibility to injury by inflammatory cytokines, particularly TNF. However, gaps remain in our understanding of alcohol-responsive mechanisms that contribute to dysregulation of genes involved in hepatic steatosis and subsequent cytokine hepatotoxicity. Cyclic AMP (cAMP), through activation of protein kinase A (PKA), has been shown to modulate genes involved in lipid metabolism and apoptosis.!cAMP levels are tightly regulated through biosynthesis by adenyl cylases (ACs) and hydrolysis by phosphodiesterases (PDEs). Our earlier work shows that expression of cAMP-specific PDE4 is significantly increased in response to alcohol exposure in monocytes/macrophages including hepatic Kupffer cells. Notably, our recent preliminary data suggest that ethanol exposure of primary mouse hepatocytes leads to a significant up-regulation of the PDE4 sub-family of enzymes, PDEA, B and D. Based on these findings we postulate that chronic ethanol feeding decreases cAMP levels in hepatocytes in a PDE4-dependent manner. There is no FDA-approved therapy for any stage of alcoholic liver disease (ALD). The most widely-used (off-label) drug therapies are glucocorticoids and pentoxifylline (PTX). Unfortunately, an important subset of AH patients treated with glucocorticoids have "steroid resistance", and some patients have contraindications to steroid therapy. PTX is a broad spectrum PDE inhibitor with only a weak PDE4 inhibitor activity, and the data available from the limited studies suggest a positive intervention effect. Hence, a more directed intervention aimed at inhibiting PDE4 may be significantly more effective. In this regard our recent preliminary data show that treatment with PDE4 specific inhibitor, rolipram, markedly inhibits hepatic steatosis in ethanol-fed animals. Our central hypothesis is that alcohol exposure increases cAMP degrading PDE4 expression in hepatocytes lowering cAMP levels with a resultant increase in lipogenesis and a decrease in fatty acid beta oxidation, leading to the development of steatosis and sensitization to TNF-induced toxicity. Importantly, as a corollary, lowering PDE4 activity may provide a significant therapeutic approach. The specific objectives of these mechanistic as well as translational studies are 1) to examine the effect of alcohol exposure on hepatocyte PDE4 expression, cAMP metabolism and development of hepatic steatosis and injury and 2) to determine the role of PDE4 subclasses and effect of PDE4 inhibition on the development of alcohol induced hepatic steatosis and injury. Our future goal is to provide a conceptual basis for targeting PDE4 activity as a clinical treatment for alcoholic patients. !

描述（由申请人提供）：酒精性肝病（ALD）仍然是美国肝脏疾病死亡的主要原因。脂肪变性是最初的、最常见的肝脏表现，发生在急性和慢性乙醇消耗的反应中。虽然脂肪变性是可逆的，但现在已经确定脂肪变性的严重程度预示着癌症的发生